The global market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment include AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Merck, Sanofi, Astellas, Chugai Pharmaceutical, Taisho Pharmaceutical, Jiangsu Hengrui Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

The SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Report

Report Metric	Details
Report Name	SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market
Segment by Type	Empagliflozin Dapagliflozin Canagliflozin Others
Segment by Application	Offline Retail Pharmacy Hospitals and Clinics E-commerce and Internet Medical Care
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Merck, Sanofi, Astellas, Chugai Pharmaceutical, Taisho Pharmaceutical, Jiangsu Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market report?

Ans: The main players in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market are AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Merck, Sanofi, Astellas, Chugai Pharmaceutical, Taisho Pharmaceutical, Jiangsu Hengrui Medicine

What are the Application segmentation covered in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market report?

Ans: The Applications covered in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market report are Offline Retail Pharmacy, Hospitals and Clinics, E-commerce and Internet Medical Care

What are the Type segmentation covered in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market report?

Ans: The Types covered in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market report are Empagliflozin, Dapagliflozin, Canagliflozin, Others

1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Overview

1.1 Product Definition

1.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type

1.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024 VS 2031)

1.2.2 Empagliflozin

1.2.3 Dapagliflozin

1.2.4 Canagliflozin

1.2.5 Others

1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application

1.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value by Application (2024 VS 2031)

1.3.2 Offline Retail Pharmacy

1.3.3 Hospitals and Clinics

1.3.4 E-commerce and Internet Medical Care

1.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts

1.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2020-2031

1.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2020-2031

1.4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competition by Manufacturers

2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2020-2025)

2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2020-2025)

2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application

2.7 Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Date of Enter into This Industry

2.8 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation and Trends

2.8.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Concentration Rate

2.8.2 The Global 5 and 10 Largest SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue

2.8.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Scenario by Region

3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2020-2031

3.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2020-2025

3.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2026-2031

3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020-2031

3.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020-2025

3.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2026-2031

3.4 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

3.4.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)

3.4.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

3.5.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)

3.5.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Region

3.6.1 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2020-2031)

3.6.3 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

3.7.1 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)

3.7.3 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country

3.8.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)

3.8.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2031)

4.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2025)

4.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2026-2031)

4.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2020-2031)

4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2020-2031)

4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2020-2025)

4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2026-2031)

4.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2020-2031)

4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2020-2031)

5 Segment by Application

5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2031)

5.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2025)

5.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2026-2031)

5.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2020-2031)

5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2020-2031)

5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2020-2025)

5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2026-2031)

5.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2020-2031)

5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2020-2031)

6 Key Companies Profiled

6.1 AstraZeneca

6.1.1 AstraZeneca Company Information

6.1.2 AstraZeneca Description and Business Overview

6.1.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.1.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.1.5 AstraZeneca Recent Developments/Updates

6.2 Johnson & Johnson

6.2.1 Johnson & Johnson Company Information

6.2.2 Johnson & Johnson Description and Business Overview

6.2.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.2.5 Johnson & Johnson Recent Developments/Updates

6.3 Boehringer Ingelheim

6.3.1 Boehringer Ingelheim Company Information

6.3.2 Boehringer Ingelheim Description and Business Overview

6.3.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.3.5 Boehringer Ingelheim Recent Developments/Updates

6.4 Merck

6.4.1 Merck Company Information

6.4.2 Merck Description and Business Overview

6.4.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.4.5 Merck Recent Developments/Updates

6.5 Sanofi

6.5.1 Sanofi Company Information

6.5.2 Sanofi Description and Business Overview

6.5.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.5.5 Sanofi Recent Developments/Updates

6.6 Astellas

6.6.1 Astellas Company Information

6.6.2 Astellas Description and Business Overview

6.6.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.6.5 Astellas Recent Developments/Updates

6.7 Chugai Pharmaceutical

6.7.1 Chugai Pharmaceutical Company Information

6.7.2 Chugai Pharmaceutical Description and Business Overview

6.7.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.7.5 Chugai Pharmaceutical Recent Developments/Updates

6.8 Taisho Pharmaceutical

6.8.1 Taisho Pharmaceutical Company Information

6.8.2 Taisho Pharmaceutical Description and Business Overview

6.8.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.8.5 Taisho Pharmaceutical Recent Developments/Updates

6.9 Jiangsu Hengrui Medicine

6.9.1 Jiangsu Hengrui Medicine Company Information

6.9.2 Jiangsu Hengrui Medicine Description and Business Overview

6.9.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio

6.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Chain Analysis

7.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process Analysis

7.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales and Marketing

7.4.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels

7.4.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors

7.5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customer Analysis

8 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Dynamics

8.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends

8.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Drivers

8.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Challenges

8.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Johnson & Johnson

Chugai Pharmaceutical

Taisho Pharmaceutical

Jiangsu Hengrui Medicine

List of Tables

Table 1. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers in 2024

Table 4. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) of Key Manufacturers (2020-2025)

Table 5. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2020-2025)

Table 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application

Table 12. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SGLT-2 Inhibitors for Type 2 Diabetes Treatment as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2020-2025) & (M Units)

Table 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2020-2025)

Table 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2026-2031) & (M Units)

Table 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2026-2031)

Table 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2020-2025)

Table 23. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2026-2031)

Table 25. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2025) & (M Units)

Table 27. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2026-2031) & (M Units)

Table 28. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2025) & (M Units)

Table 32. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2026-2031) & (M Units)

Table 33. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2020-2025) & (M Units)

Table 37. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2026-2031) & (M Units)

Table 38. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2025) & (M Units)

Table 42. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2026-2031) & (M Units)

Table 43. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2025) & (M Units)

Table 47. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2026-2031) & (M Units)

Table 48. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2020-2025)

Table 51. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2026-2031)

Table 52. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2020-2025)

Table 53. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2026-2031)

Table 54. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2020-2025)

Table 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2026-2031)

Table 56. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2020-2025)

Table 57. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2026-2031)

Table 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2020-2025)

Table 59. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2026-2031)

Table 60. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2020-2025)

Table 61. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2026-2031)

Table 62. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2020-2025)

Table 63. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2026-2031)

Table 64. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2020-2025)

Table 65. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2026-2031)

Table 66. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2020-2025)

Table 67. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2026-2031)

Table 68. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2020-2025)

Table 69. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2026-2031)

Table 70. AstraZeneca Company Information

Table 71. AstraZeneca Description and Business Overview

Table 72. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 73. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 74. AstraZeneca Recent Developments/Updates

Table 75. Johnson & Johnson Company Information

Table 76. Johnson & Johnson Description and Business Overview

Table 77. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 78. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 79. Johnson & Johnson Recent Developments/Updates

Table 80. Boehringer Ingelheim Company Information

Table 81. Boehringer Ingelheim Description and Business Overview

Table 82. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 83. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 84. Boehringer Ingelheim Recent Developments/Updates

Table 85. Merck Company Information

Table 86. Merck Description and Business Overview

Table 87. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 88. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 89. Merck Recent Developments/Updates

Table 90. Sanofi Company Information

Table 91. Sanofi Description and Business Overview

Table 92. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 93. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 94. Sanofi Recent Developments/Updates

Table 95. Astellas Company Information

Table 96. Astellas Description and Business Overview

Table 97. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 98. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 99. Astellas Recent Developments/Updates

Table 100. Chugai Pharmaceutical Company Information

Table 101. Chugai Pharmaceutical Description and Business Overview

Table 102. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 103. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 104. Chugai Pharmaceutical Recent Developments/Updates

Table 105. Taisho Pharmaceutical Company Information

Table 106. Taisho Pharmaceutical Description and Business Overview

Table 107. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 108. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 109. Taisho Pharmaceutical Recent Developments/Updates

Table 110. Jiangsu Hengrui Medicine Company Information

Table 111. Jiangsu Hengrui Medicine Description and Business Overview

Table 112. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2020-2025)

Table 113. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product

Table 114. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List

Table 118. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List

Table 119. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Trends

Table 120. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Drivers

Table 121. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Challenges

Table 122. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of SGLT-2 Inhibitors for Type 2 Diabetes Treatment

Figure 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Type: 2024 & 2031

Figure 4. Empagliflozin Product Picture

Figure 5. Dapagliflozin Product Picture

Figure 6. Canagliflozin Product Picture

Figure 7. Others Product Picture

Figure 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Application: 2024 & 2031

Figure 10. Offline Retail Pharmacy

Figure 11. Hospitals and Clinics

Figure 12. E-commerce and Internet Medical Care

Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2020-2031) & (US$ Million)

Figure 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2020-2031) & (M Units)

Figure 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) & (2020-2031)

Figure 17. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Report Years Considered

Figure 18. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Manufacturers in 2024

Figure 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players: Market Share by Revenue in SGLT-2 Inhibitors for Type 2 Diabetes Treatment in 2024

Figure 21. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2020-2031)

Figure 24. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2020-2031)

Figure 25. United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2020-2031)

Figure 28. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2020-2031)

Figure 29. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2020-2031)

Figure 36. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2020-2031)

Figure 44. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2020-2031)

Figure 45. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2020-2031)

Figure 50. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type (2020-2031)

Figure 54. Global Revenue Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type (2020-2031)

Figure 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application (2020-2031)

Figure 57. Global Revenue Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application (2020-2031)

Figure 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2020-2031)

Figure 59. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oral Anti Diabetic Drug Market Insights Forecast to 2030

Global Oral Glucose Market Research Report 2025

Global Sitagliptin Tablet Market Research Report 2025

Global Liraglutide Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global SGLT2 Inhibitor Market Insights Forecast to 2030

Global Sodium dependent Glucose Co transporter 2 SGLT2 Market Research Report 2024

Global DPP 4 Inhibitors for Type 2 Diabetes Treatment Market Research Report 2025

Global Empagliflozin Tablets Market Research Report 2025

Global Tofogliflozin Market Research Report 2025

Global Dapagliflozin Tablets Market Research Report 2024

Global Sodium Glucose Cotransporter 2 SGLT 2 Inhibitors Market Insights Forecast to 2030

Global Type 2 Diabetes Therapeutics Market Research Report 2025

Global SGLT2 Inhibitors Treatment Market Research Report 2024

Dapagliflozin API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical Grade Dapagliflozin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

DPP 4 Inhibitor Hypoglycemic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Diabetes Treatment Devices Market Research Report 2024

Global Combination Anti Diabetes Drugs Market Research Report 2025

Antidiabetic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions